RT Journal Article
SR Electronic
A1 Buckley, Rita
T1 Transitioning to Denosumab from Continuous Alendronate Therapy Further Improves BMD in Postmenopausal Women with Osteoporosis
JF MD Conference Express
YR 2011
FD SAGE Publications
VO 11
IS 5
SP 13
OP 14
DO 10.1177/155989771105009
UL http://mdc.sagepub.com/content/11/5/13.2.abstract
AB This article presents findings on the efficacy and safety of a shift from alendronate (ALN) to denosumab (DMAb) in a subset of women from the 1-year Study of Transitioning from Alendronate to Denosumab [STAND; NCT00377819] trial who transitioned to DMAb after 5 or more years of continuous ALN therapy.